28127799|t|TBL1XR1 predicts isolated tumor cells and micrometastasis in patients with TNM stage I/II colorectal cancer
28127799|a|A considerable number of early stage colorectal cancer (CRC) patients may develop cancer relapse or metastasis after curative surgery. Isolated tumor cells (ITC) and micrometastasis in lymph nodes (LNMM), which are undetectable by conventional pathological examination, may be one primary reason. Detection of ITC / LNMM is time-consuming and cost-ineffective, we aimed to find biomarkers in primary CRC tissues to help predicting ITC / LNMM status. We enrolled 137 node-negative patients with early stage CRC in this study. Existence of ITC / LNMM was identified by immunohistological staining with cytokeratin 20 in resected lymph nodes. Expression of transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) in primary CRC tissues was also investigated. Chi-square test was performed to reveal the correlations between ITC / LNMM and clinicopathological characteristics. Univariate and multivariate analyses were used to determine independent prognostic factors. Knock-down experiment together with proliferation and invasion assays were carried out to explore molecular mechanisms between TBL1XR1 and ITC / LNMM. 29.2% (40/137) patients were identified as ITC / LNMM positive and most of them (32/40 cases, 80%) showed high TBL1XR1 expression in primary CRC tissues. Both ITC / LNMM and TBL1XR1 expression were independent prognostic factors for disease relapse or metastasis. In vitro experiments demonstrated that TBL1XR1 can regulate the expression of VEGF-C and epithelial-mesenchymal transition proteins, thus mediate the process of lymph node metastasis. Identification of ITC / LNMM is significant in evaluating clinical outcome and guiding adjuvant chemotherapy for early stage CRC patients. TBL1XR1 overexpression in CRC tissues can serve as an efficient biomarker to predict the status of ITC / LNMM.
28127799	0	7	TBL1XR1	T116,T123	C1176196
28127799	8	16	predicts	T078	C0681842
28127799	17	37	isolated tumor cells	T033	C3829491
28127799	42	57	micrometastasis	T033	C1513276
28127799	61	69	patients	T101	C0030705
28127799	75	89	TNM stage I/II	T185	C1515169
28127799	90	107	colorectal cancer	T191	C1527249
28127799	110	129	considerable number	T081	C0237753
28127799	133	144	early stage	T079	C2363430
28127799	145	162	colorectal cancer	T191	C1527249
28127799	164	167	CRC	T191	C1527249
28127799	169	177	patients	T101	C0030705
28127799	190	204	cancer relapse	T191	C0699753
28127799	208	218	metastasis	T191	C0027627
28127799	225	241	curative surgery	T061	C1511562
28127799	243	263	Isolated tumor cells	T033	C3829491
28127799	265	268	ITC	T033	C3829491
28127799	274	289	micrometastasis	T033	C1513276
28127799	293	304	lymph nodes	T023	C0024204
28127799	306	310	LNMM	T191	C0024232
28127799	323	335	undetectable	T201	C3827727
28127799	339	351	conventional	T080	C0439858
28127799	352	376	pathological examination	T058	C0582103
28127799	389	403	primary reason	T078	C1549995
28127799	405	414	Detection	T061	C1511790
28127799	418	421	ITC	T033	C3829491
28127799	424	428	LNMM	T191	C0024232
28127799	432	446	time-consuming	T080	C3827829
28127799	451	467	cost-ineffective	T081	C0392762
28127799	472	477	aimed	T078	C1947946
28127799	481	485	find	T033	C0243095
28127799	486	496	biomarkers	T201	C0005516
28127799	500	507	primary	T080	C0205225
28127799	508	511	CRC	T191	C1527249
28127799	512	519	tissues	T024	C0040300
28127799	528	538	predicting	T078	C0681842
28127799	539	542	ITC	T033	C3829491
28127799	545	549	LNMM	T191	C0024232
28127799	550	556	status	T080	C0449438
28127799	574	587	node-negative	T033	C0678034
28127799	588	596	patients	T101	C0030705
28127799	602	613	early stage	T079	C2363430
28127799	614	617	CRC	T191	C1527249
28127799	626	631	study	T062	C0681814
28127799	633	642	Existence	T077	C2987476
28127799	646	649	ITC	T033	C3829491
28127799	652	656	LNMM	T191	C0024232
28127799	661	671	identified	T080	C0205396
28127799	675	702	immunohistological staining	T059	C0487602
28127799	708	722	cytokeratin 20	T116,T123	C0219510
28127799	726	734	resected	T080	C1521996
28127799	735	746	lymph nodes	T023	C0024204
28127799	748	758	Expression	T045	C1171362
28127799	762	803	transducin (β)-like 1 X-linked receptor 1	T116,T123	C1176196
28127799	805	812	TBL1XR1	T116,T123	C1176196
28127799	817	824	primary	T080	C0205225
28127799	825	828	CRC	T191	C1527249
28127799	829	836	tissues	T024	C0040300
28127799	846	858	investigated	T169	C1292732
28127799	860	875	Chi-square test	T170	C0008041
28127799	880	889	performed	T169	C0884358
28127799	893	899	reveal	T080	C0443289
28127799	904	916	correlations	T080	C1707520
28127799	925	928	ITC	T033	C3829491
28127799	931	935	LNMM	T191	C0024232
28127799	940	959	clinicopathological	T169	C1521733
28127799	960	975	characteristics	T080	C1521970
28127799	977	987	Univariate	T062	C0683962
28127799	992	1013	multivariate analyses	T081	C0026777
28127799	1037	1048	independent	T169	C0332291
28127799	1049	1067	prognostic factors	T201	C1514474
28127799	1069	1090	Knock-down experiment	T063	C2350567
28127799	1091	1099	together	T080	C1883357
28127799	1105	1118	proliferation	T046	C0334094
28127799	1123	1131	invasion	T046	C2699153
28127799	1132	1138	assays	T059	C0005507
28127799	1167	1187	molecular mechanisms	T044	C3537153
28127799	1196	1203	TBL1XR1	T116,T123	C1176196
28127799	1208	1211	ITC	T033	C3829491
28127799	1214	1218	LNMM	T191	C0024232
28127799	1235	1243	patients	T101	C0030705
28127799	1249	1259	identified	T080	C0205396
28127799	1263	1266	ITC	T033	C3829491
28127799	1269	1273	LNMM	T191	C0024232
28127799	1274	1282	positive	T033	C1446409
28127799	1326	1330	high	T080	C0205250
28127799	1331	1338	TBL1XR1	T116,T123	C1176196
28127799	1339	1349	expression	T045	C1171362
28127799	1353	1360	primary	T080	C0205225
28127799	1361	1364	CRC	T191	C1527249
28127799	1365	1372	tissues	T024	C0040300
28127799	1374	1378	Both	T080	C1706086
28127799	1379	1382	ITC	T033	C3829491
28127799	1385	1389	LNMM	T191	C0024232
28127799	1394	1401	TBL1XR1	T116,T123	C1176196
28127799	1402	1412	expression	T045	C1171362
28127799	1418	1429	independent	T169	C0332291
28127799	1430	1448	prognostic factors	T201	C1514474
28127799	1453	1468	disease relapse	T047	C0277556
28127799	1472	1482	metastasis	T191	C0027627
28127799	1484	1492	In vitro	T080	C1533691
28127799	1493	1504	experiments	T062	C0681814
28127799	1505	1517	demonstrated	T080	C0443289
28127799	1523	1530	TBL1XR1	T116,T123	C1176196
28127799	1535	1543	regulate	T169	C2587213
28127799	1548	1558	expression	T045	C1171362
28127799	1562	1568	VEGF-C	T116,T123	C0388911
28127799	1573	1595	epithelial-mesenchymal	T025	C1181295
28127799	1596	1615	transition proteins	T116,T123	C0033684
28127799	1634	1641	process	T067	C1522240
28127799	1645	1666	lymph node metastasis	T191	C0024232
28127799	1668	1682	Identification	T080	C0205396
28127799	1686	1689	ITC	T033	C3829491
28127799	1692	1696	LNMM	T191	C0024232
28127799	1700	1711	significant	T078	C0750502
28127799	1726	1742	clinical outcome	T169	C1274040
28127799	1755	1776	adjuvant chemotherapy	T061	C0085533
28127799	1781	1792	early stage	T079	C2363430
28127799	1793	1796	CRC	T191	C1527249
28127799	1797	1805	patients	T101	C0030705
28127799	1807	1814	TBL1XR1	T116,T123	C1176196
28127799	1815	1829	overexpression	T045	C0017262
28127799	1833	1836	CRC	T191	C1527249
28127799	1837	1844	tissues	T024	C0040300
28127799	1861	1870	efficient	T080	C0442799
28127799	1871	1880	biomarker	T201	C0005516
28127799	1884	1891	predict	T078	C0681842
28127799	1896	1902	status	T080	C0449438
28127799	1906	1909	ITC	T033	C3829491
28127799	1912	1916	LNMM	T191	C0024232